BMS-830216
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 09, 2023
Computational prediction of analog compounds of the membrane protein MCHR1 antagonists ALB-127158 and KRX-104130.
(PubMed, J Bioenerg Biomembr)
- "Known MCHR1 antagonists include BMS-830216, GW-856464, NGD-4715, ALB-127158, and AMG 076, but many have failed phase-I clinical studies. In addition, all ligands remained stable in putative binding site. It has been suggested that PV-002757495233 and Z1922310273 compounds can be evaluated as MCHR1 antagonists when all these outputs are considered in melting pots."
Journal • Cardiovascular • Genetic Disorders • Metabolic Disorders • Obesity
July 06, 2011
Safety, pharmacokinetics and pharmacodynamics study to evaluate BMS-830216 in obese subjects
(clinicaltrials.gov)
- P1/2, N=113; Active, not recruiting → Completed
Trial completion • Diabetes
February 05, 2019
Some Observations on the Liquid Crystalline and Gel Behaviors of Aqueous Dispersions of a Prodrug.
(PubMed, Drug Dev Ind Pharm)
- "As indicated by SAXS, the lamellar phase formed seems to have two d-spacing values (∼5 nm and ∼10 nm (weak), which seems to correspond to two molecules connected tail by tail (5 nm). Further investigation is needed for phase identification, as their properties can affect the physical behavior of BMS-830216 in the development of pharmaceutical dosage forms."
Journal
1 to 3
Of
3
Go to page
1